Abstract
A once-daily controlled-release formulation of MK-8189, a phosphodiesterase 10A inhibitor, achieves an optimal enzyme occupancy, pharmacokinetic profile and is well-tolerated
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
